Dimerix to progress its discovery platform with ARC Grant
A consortium led by Dimerix Limited’s (ASX:DXB) Chief Scientific Advisor, Associate Professor Kevin Pfleger (UWA and Harry Perkins Medical Research Institute) has been awarded a $499,000 Linkage Grant by the Australian Research Council.
The money will go towards a consortium that includes Dimerix working with the Harry Perkins Institute of Medical Research and the University of Western Australia (UWA).
The ‘Development of Technologies to Monitor Multimolecular Complexes’ grant will be paid over three years and will help to expedite development of Dimerix’s discovery platform in new ways for new applications.
Dimerix Executive Chairman, Dr James Williams, a Partner Investigator of the Linkage Grant, told the market, “These additional funds will further enable to engage with leaders in the field, to progress the scientific excellence of its discovery assay potential as well as routes to commercialisation.
“We believe it will further enable Dimerix to make significant progress towards realising the commercial value of its discovery platform capabilities.”
Several leaders in the field make up the UWA consortium and include Associate Professor Kevin Pfleger and key scientists at the University of Queensland, University of Nottingham (UK), leading instrumentation manufacturer BMG Labtech and global reagent supplier Promega Corporation.
Dimerix has committed $100,000 research funding to support the project.
The funding has come at good time for Dimerix as it continues preparations for talks with US FDA in a pre-investigational new drug application meeting in relation to the Development Plan for DMX-200, which combines two existing drugs one of which is marketed to treat hypertension and diabetic nephropathy in certain patients.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.